Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 5/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | NPR1 | P16066 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112744 | 0.91 | GPR55 (0.38) | KDM4ETSHRMAPK1HSD17B10GPR55 | |
| SCHEMBL1793422 | 0.85 | KDM4E (0.38) | KDM4ETSHRMAPK1HSD17B10ADORA2A | |
| SCHEMBL5116589 | 0.81 | KDM4E (0.38) | KDM4ETSHRMAPK1HSD17B10ADORA2A | |
| SCHEMBL1792108 | 0.79 | TP53 (0.38) | KDM4ETSHRMAPK1HSD17B10ADORA2A | |
| SCHEMBL1791425 | 0.79 | GPR55 (0.35) | GPR55ADORA2AADORA2BGRK6ADORA3 | |
| SCHEMBL1794804 | 0.78 | EGFR (0.34) | HSD17B10GPR55MAP4K4NPR1 | |
| SCHEMBL1794395 | 0.78 | EGFR (0.34) | HSD17B10GPR55MAP4K4NPR1 | |
| SCHEMBL1789999 | 0.78 | NR1H2 (0.34) | HSD17B10MAP4K4NPR1 | |
| SCHEMBL12613108 | 0.77 | SYK (0.37) | NPR1 | |
| SCHEMBL1790309 | 0.77 | KDM4E (0.36) | KDM4ETSHRMAPK1HSD17B10ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, CYP2S1, DPYD | KDM4E 3849/4885TSHR 2245/4885MAPK1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.